Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis.
AVT, antiviral therapy
Antiviral efficacy
BMI, body mass index
CHB, chronic hepatitis B
CI, confidence interval
ETV, entecavir
HBV infection
HBV, hepatitis B virus
HBeAg, hepatitis B e antigen
HBsAg, hepatitis B surface antigen
HCC, hepatocellular carcinoma
HDL, high-density lipoprotein
HDL-C, high-density lipoprotein-cholesterol
HR, hazard ratio
HS, hepatis steatosis
Hepatocellular carcinoma
LDL-C, low-density lipoprotein cholesterol
Liver fibrosis
NA, nucleos(t)ide analogue
NAFLD, nonalcoholic fatty liver disease
NASH, nonalcoholic steatohepatitis
NR, not reported
Nonalcoholic fatty liver disease
OR, odds ratio
PEG-IFN, pegylated interferon
TAF, tenofovir alafenamide
TDF, tenofovir
TLR4, Toll-Like Receptor 4
aHR, adjusted hazard ratio
non-HDL-C, non-high-density lipoprotein-cholesterol
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
03
11
2022
revised:
07
01
2023
accepted:
18
01
2023
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
8
2
2023
Statut:
epublish
Résumé
Hepatitis B virus (HBV) infection is still one kind of the infectious diseases that seriously threaten human health. Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. HBV infection complicated with NAFLD is increasingly common. This review mainly describes the interaction between HBV infection and NAFLD, the interaction between steatosis and antiviral drugs, and the prognosis of HBV infection complicated with NAFLD. Most studies suggest that HBV infection may reduce the incidence of NAFLD. NAFLD can promote the spontaneous clearance of hepatitis B surface antigen (HBsAg), but whether it affects antiviral efficacy has been reported inconsistently. HBV infection combined with NAFLD can promote the progression of liver fibrosis, especially in patients with severe steatosis. The outcome of HBV infection combined with NAFLD predisposing to the progression of HCC remains controversial.
Identifiants
pubmed: 36747946
doi: 10.1016/j.heliyon.2023.e13113
pii: S2405-8440(23)00320-1
pmc: PMC9898750
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e13113Informations de copyright
© 2023 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biosci Rep. 2021 Dec 22;41(12):
pubmed: 34918746
J Viral Hepat. 2019 Jul;26(7):818-827
pubmed: 30895682
J Hepatol. 2020 Oct;73(4):800-806
pubmed: 32504663
Clin Mol Hepatol. 2016 Sep;22(3):339-349
pubmed: 27729627
Postgrad Med. 2016 Sep;128(7):697-700
pubmed: 27499150
Can J Cardiol. 2021 May;37(5):733-743
pubmed: 33610690
J Formos Med Assoc. 2022 Jul;121(7):1273-1282
pubmed: 34625346
Turk J Gastroenterol. 2016 Jan;27(1):42-6
pubmed: 26674977
Am J Gastroenterol. 2021 Aug 1;116(8):1686-1697
pubmed: 33840726
Clin Gastroenterol Hepatol. 2018 Apr;16(4):575-583.e2
pubmed: 28970146
Gut. 2020 Mar;69(3):564-568
pubmed: 31366455
Hepatology. 2017 Mar;65(3):828-835
pubmed: 28035771
J Clin Gastroenterol. 2007 May-Jun;41(5):513-7
pubmed: 17450036
Int J Obes (Lond). 2007 May;31(5):871-5
pubmed: 17047638
Clin Mol Hepatol. 2019 Mar;25(1):52-64
pubmed: 30360031
PLoS One. 2013 Aug 22;8(8):e72049
pubmed: 23991037
BMC Gastroenterol. 2020 May 12;20(1):146
pubmed: 32397963
Hepat Mon. 2015 May 23;15(5):e27909
pubmed: 26045709
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Liver Int. 2009 Jul;29(6):878-83
pubmed: 19192167
Clin Gastroenterol Hepatol. 2022 Feb;20(2):427-437.e5
pubmed: 33962041
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
Gastroenterology. 2007 May;132(5):1955-67
pubmed: 17484888
J Hepatol. 2017 Oct;67(4):862-873
pubmed: 28642059
Metabolism. 2013 Feb;62(2):220-5
pubmed: 22938729
Nutrition. 2016 Nov-Dec;32(11-12):1206-10
pubmed: 27283043
J Viral Hepat. 2020 Dec;27(12):1297-1305
pubmed: 32668489
J Hepatocell Carcinoma. 2022 Apr 11;9:301-313
pubmed: 35433529
J Mol Biol. 2010 Apr 9;397(4):917-31
pubmed: 20156456
J Hepatol. 2012 Mar;56(3):533-40
pubmed: 22027575
J Viral Hepat. 2019 Jan;26(1):162-169
pubmed: 30267602
Front Cell Infect Microbiol. 2022 Jan 17;11:733348
pubmed: 35111690
Eur J Intern Med. 2015 Jan;26(1):30-6
pubmed: 25553983
J Formos Med Assoc. 2020 Oct;119(10):1476-1482
pubmed: 32499209
PLoS One. 2022 Jan 20;17(1):e0261760
pubmed: 35051189
Liver Int. 2019 Jan;39(1):70-80
pubmed: 30025200
Hepatol Int. 2018 Sep;12(5):438-446
pubmed: 29974410
Hepatol Int. 2021 Aug;15(4):901-911
pubmed: 34152534
Bull World Health Organ. 2019 Mar 1;97(3):230-238
pubmed: 30992636
J Gastroenterol Hepatol. 2012 Dec;27(12):1858-64
pubmed: 22989301
Clin Mol Hepatol. 2022 Apr;28(2):254-264
pubmed: 34959261
J Gastroenterol Hepatol. 2017 Mar;32(3):667-676
pubmed: 27547913
Liver Int. 2017 Apr;37(4):542-551
pubmed: 27740738
Crit Rev Food Sci Nutr. 2021;61(10):1651-1669
pubmed: 32515660
Gut. 2015 Dec;64(12):1972-84
pubmed: 26048673
Dig Dis Sci. 2013 Jan;58(1):275-81
pubmed: 22903182
J Viral Hepat. 2018 Jan;25(1):97-104
pubmed: 28772340
Aliment Pharmacol Ther. 2021 Nov;54(9):1100-1109
pubmed: 34469587
Liver Int. 2022 Feb;42(2):320-329
pubmed: 34679254
Transplant Proc. 2015 Dec;47(10):2886-91
pubmed: 26707308
Dig Dis Sci. 2014 Oct;59(10):2571-9
pubmed: 24838496
Int J Clin Pract. 2021 Dec;75(12):e14899
pubmed: 34547163
J Hepatol. 2021 Sep;75(3):706-717
pubmed: 34051332
Clin Microbiol Rev. 2020 Feb 26;33(2):
pubmed: 32102898
J Infect Dis. 2021 Dec 1;224(11):1890-1899
pubmed: 33999179
J Formos Med Assoc. 2022 Aug;121(8):1478-1487
pubmed: 34764005
JGH Open. 2020 Dec 19;5(2):258-263
pubmed: 33553665
J Virol. 2015 Dec 04;90(4):1729-40
pubmed: 26637457
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Oct;27(5):332-5
pubmed: 24645315
J Viral Hepat. 2021 Nov;28(11):1545-1553
pubmed: 34382730
J Clin Gastroenterol. 2020 Aug;54(7):633-641
pubmed: 31033805
Liver Int. 2022 Jul;42(7):1517-1527
pubmed: 35343041
PLoS One. 2012;7(3):e34198
pubmed: 22479562
Liver Int. 2020 May;40(5):1052-1061
pubmed: 32086988
Clin Mol Hepatol. 2019 Sep;25(3):283-293
pubmed: 30419649
Antiviral Res. 2020 Oct;182:104925
pubmed: 32866519
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
Aliment Pharmacol Ther. 2017 Sep;46(6):599-604
pubmed: 28707319
J Infect Dis. 2021 Jul 15;224(2):294-302
pubmed: 33249474
Front Microbiol. 2021 Mar 11;12:636897
pubmed: 33776969